Roderick de Greef - 24 Feb 2026 Form 4 Insider Report for BIOLIFE SOLUTIONS INC (BLFS)

Signature
/s/ Roderick de Greef
Issuer symbol
BLFS
Transactions as of
24 Feb 2026
Net transactions value
-$3,469,889
Form type
4
Filing time
26 Feb 2026, 17:55:41 UTC
Previous filing
13 Nov 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
DE GREEF RODERICK President and CEO, Director 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL /s/ Roderick de Greef 26 Feb 2026 0001241181

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLFS Common Stock Award +118,730 +30% 508,728 24 Feb 2026 Direct F1
transaction BLFS Common Stock Award +170,291 +33% 679,019 24 Feb 2026 Direct F2
transaction BLFS Common Stock Tax liability $1,517,776 -67,010 -9.9% $22.65 612,009 24 Feb 2026 Direct F3
transaction BLFS Common Stock Award +219,024 +36% 831,033 24 Feb 2026 Direct F4
transaction BLFS Common Stock Tax liability $1,952,113 -86,186 -10% $22.65 744,847 24 Feb 2026 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2026 compensation.
F2 The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant, the restricted stock vested as to approximately 156% of the number of shares granted based on the registrant's total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F3 Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
F4 The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant, the restricted stock vested as to 200% of the number of shares granted based on specific performance metrics of the registrant during the period beginning on January 1, 2024 through December 31, 2025.
F5 Represents shares withheld to cover tax withholding obligations in connection with the vesting of the performance-based restricted stock award.